Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres








Gamme d'année
2.
Article | IMSEAR | ID: sea-195430

RÉSUMÉ

Background & objectives: Brucellosis can lead to haematological abnormalities including cytopenia confusing with haematological malignancies. The aim of this study was to compare the main characteristics of brucellosis patients without cytopenia (Group 1) and with cytopenia (Group 2). Methods: This five-year period study which was performed in two referral hospitals in Turkey, included all adult brucellosis patients. Abnormally, low counts of leucocyte or haemoglobin or platelets in a patient were considered as cytopenia. The demographics, clinical, laboratory, treatment and outcome data were analyzed. Results: A total of 484 brucellosis patients were enrolled. Among the cases, 162 (33.5%) of them had cytopenia. One hundred and four (21.5%) had anaemia, 88 (18.8%) had thrombocytopenia, 71 (14.6%) had leucopenia and 28 (5.8%) had pancytopenia. The mean age of group 2 was 35.01�.05 yr and it was 33.31�.39 yr in group 1. While there was no difference between the groups in terms of duration of treatment, the median length of hospital stay (LOS) was significantly longer in group 2 (9 vs 10 days; P<0.001). The most frequently applied combination therapy consisted of doxycycline plus rifampicin and doxycycline plus streptomycin regimens. No significant difference was observed in terms of duration of treatment, LOS and restoration time of cytopenia between the patients who received either of these combinations. Interpretation & conclusions: Our findings suggested that the patients with cytopenia should be investigated for brucellosis, especially if living in, or with a history of travel to, endemic areas, in view of the increase in world travel.

3.
Int. j. morphol ; 34(2): 460-464, June 2016. ilus
Article de Anglais | LILACS | ID: lil-787021

RÉSUMÉ

A total of 32 Wistar rats were divided into four equal groups: (I) sham, (II) ischemia, (III) reperfusion and (IV) Potentilla fulgens. In groups I and II, ovary torsion was not performed and no drug was administered. In group III, 1 h of ischemia and 2 h of reperfusion were performed and no drug was given. Group IV received 400 mg/kg/day Potentilla fulgens intraperitoneally 5 days before Ischemia-reperfusion. All the parameters were observed to be significantly decreased (P<0.05) in all the experimental groups compared to the control group. In the sections of the ischemia-reperfusion group, degeneration of epithelium, dilation of blood vessels were observed. Potentilla fulgens administration reduced the morphological changes by induced I/R; in particular, infiltration, hemorrhage and vascular dilatation were decreased. Potentilla fulgens application during torsion, it plays an important role in maintaining the epithelial structure with E-cadherin expression. We suggest that PECAM-1(CD31) are a regulator of the microvascular response of the tubal mucosa.


Un total de 32 ratas Wistar fueron divididas en cuatro grupos: (I) Sham, (II) isquemia, (III) reperfusión y (IV) Potentilla fulgens. En los grupos I y II, no se realizó la torsión de ovario y ni se administró ningún tipo de fármaco. En el grupo III, se produjo isquemia por 1 h seguido de reperfusión por 2 h (I/R), sin administracion de fármacos. El grupo IV recibió 400 mg/kg por día de Potentilla fulgens vía intraperitoneal durante cinco días previo al protocolo de isquemia-reperfusión. Se observó que todos los parámetros disminuyeron significativamente (P <0,05) en todos los grupos experimentales en comparación con el grupo control. En las secciones del grupo de isquemia-reperfusión, se observó degeneración del epitelio y dilatación de los vasos sanguíneos. La administración de Potentilla fulgens reduce los cambios morfológicos inducidos por I/R; en particular, la infiltración, la hemorragia y la dilatación vascular. La aplicación de Potentilla fulgens durante la torsión, desempeña un papel importante en el mantenimiento de la estructura epitelial con la expresión de E-cadherina. Sugerimos que PECAM-1 (CD31) es un regulador de la respuesta microvascular de la mucosa tubárica.


Sujet(s)
Animaux , Femelle , Rats , Trompes utérines/effets des médicaments et des substances chimiques , Extraits de plantes/administration et posologie , Potentilla/composition chimique , Lésion d'ischémie-reperfusion/anatomopathologie , Immunohistochimie , Ovariectomie , Rat Wistar , Lésion d'ischémie-reperfusion/traitement médicamenteux
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE